Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03606798
Other study ID # CHUBX2015/06
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 21, 2018
Est. completion date October 6, 2021

Study information

Verified date March 2022
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fronto-Temporal Lobar Degeneration (FTLD) refers to 3 categories of neurodegenerative diseases generally occurring between 55 and 65 years: Fronto-Temporal Dementia(FTD), Primary Progressive Aphasia (PPA), Semantic Dementia (SD). Clinical expression is substantially variable among individuals, but in most cases, behavioural disorders and personality changes are prominent. FTLD is poorly known by general public including health care professionals. Currently, the French health system does not meet the needs and expectations of patients and their families


Description:

Patients with FTLD and their caregivers need to be recognized and supported through specific and tailored made actions provided by expert teams. The main objective of our study is to evaluate the effectiveness of a 6-month personalized multidisciplinary care provided to the dyad FTLD patient and caregiver on patient's behavioural disorders. The secondary objectives are to assess the impact of this program on patient's cognitive deterioration, functional autonomy and behavioral problems, as well as caregiver's depressive symptomatology and sense of competence


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date October 6, 2021
Est. primary completion date October 6, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: Patients - Fronto-Temporal Lobar Degeneration diagnoses - Men or women aged 18 and over Caregiver • Spouse, brother, sister, child living at patient's home and can provide the medical team of reliable information on the status of their parent. Exclusion criteria : Patient - Patient institutionalized - Pregnant or breast-feeding woman - Psychotic syndrome - Severe and unstable general medical condition - Patient bedridden Caregiver - Persons under legal protection - Severe and unstable general medical condition - Pregnant or breast-feeding woman

Study Design


Related Conditions & MeSH terms


Intervention

Other:
3 Home visits made by a psychologist
Patient and caregiver interviews with a psychologist at home

Locations

Country Name City State
France Bordeaux University Hospital Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuropsychiatric Inventory (NPI) Assessment of neuropsychiatric symptomatology 6 months
Secondary Neuropsychiatric Inventory (NPI) Assessment of neuropsychiatric symptomatology 12 months
Secondary Mini Mental State Examination 6 months and 12 months
Secondary Frontal Behavioral Inventory 6 months and 12 months
Secondary Frontal Assessment Battery 6 months and 12 months
Secondary Geriatric Depression Scale Score ( From 0 to 30) Score : 0 - 5 : normal Score : 5 - 9 : light depression Score : 10 - 30 : severe depression 6 months and 12 months
Secondary Sense of Competence Questionnaire (SCQ) 6 months and 12 months
Secondary Quality of Life Questionnaire (QoL-AD) 6 months and 12 months
Secondary Hierarchical scale of internality for elderly people (EHIPA) score ( From 0 to 22) The score varies from 0 to 22. A high score corresponding to an important internality 6 months and 12 months
See also
  Status Clinical Trial Phase
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Active, not recruiting NCT04516499 - Neurofilament Surveillance Project (NSP)
Recruiting NCT05456503 - PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620 Phase 3
Recruiting NCT03030586 - ADDIA Proof-of-Performance Clinical Study
Completed NCT02590276 - Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS) N/A
Completed NCT00677885 - P-glycoprotein Function in Brain Diseases
Completed NCT02333942 - Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
Completed NCT00187525 - A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration Phase 4
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Completed NCT02213458 - Care Ecosystem: Navigating Patients and Families Through Stages of Care N/A
Completed NCT04287738 - Care Ecosystem: Navigating Patients and Families Through Stages of Care, Extension Trial N/A
Active, not recruiting NCT04937452 - Dopaminergic Therapy for Frontotemporal Dementia Patients Phase 2
Recruiting NCT01962064 - Social Cognition in Ageing and in Frontotemporal Lobar Degeneration N/A
Recruiting NCT05956834 - A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
Completed NCT00088751 - Treatment Study of Frontotemporal Dementia N/A
Enrolling by invitation NCT04635540 - Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease N/A
Completed NCT00604591 - Effects of Tolcapone on Frontotemporal Dementia Phase 2
Completed NCT03508024 - Patients With Alzheimer's Disease or Related Youth Disease
Completed NCT00613119 - PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
Recruiting NCT02964611 - Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration